Quantcast
Last updated on April 24, 2014 at 12:48 EDT

Latest Sanofi-Aventis Stories

2011-06-22 09:00:00

Strategic Canadian asset puts Ontario at the heart of global vaccine innovation To view the Social Media Release, click here: http://smr.newswire.ca/en/sanofi-pasteur/sanofi-pasteur-opens-100m-rd-centre-in-canada TORONTO, June 22, 2011 /PRNewswire/ - Mark Lievonen, President of Sanofi Pasteur Limited, and Premier Dalton McGuinty today opened a $101 million dollar vaccine research and development facility at Sanofi Pasteur's Connaught Campus in north Toronto. This new facility...

2011-06-22 05:00:00

FRANKLIN LAKES, N.J., June 22, 2011 /PRNewswire/ -- Sanofi (NYSE: SNY), Medco Health Solutions, Inc. (NYSE: MHS) and its wholly owned subsidiary, United BioSource Corporation (UBC), announced they have entered into a global, multi-year agreement to support the real-world evidence assessments during Sanofi product development and pre-/post-approval processes that support improvements in the overall quality of patient care. (Logo: http://photos.prnewswire.com/prnh/20100609/MEDCOLOGO )...

2011-06-17 08:30:00

CHICAGO, June 17, 2011 /PRNewswire/ -- Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Bristol-Myers Squibb Company (NYSE: BMY), Pfizer (NYSE: PFE), AstraZeneca (NYSE: AZN), Sanofi-Aventis (NYSE: SNY) and NCR Corp. (NYSE: NCR). (Logo: http://photos.prnewswire.com/prnh/20101027/ZIRLOGO) Get the most...

2011-06-16 07:00:00

PARIS, June 16, 2011 /PRNewswire/ -- Sanofi (EURONEXT: SAN and NYSE: SNY) announced today that it has entered into a two-year research collaboration with the biopharmaceutical company Audion Therapeutics (Audion) to develop potential treatments for hearing loss through the optimization of small molecules by using a regenerative medicine approach. (Logo: http://photos.prnewswire.com/prnh/20110616/NY20158LOGO ) This collaborative research will utilize technology developed at the...

2011-06-15 08:13:00

ALLEGAN, Mich., June 15, 2011 /PRNewswire/ -- Perrigo Company (Nasdaq: PRGO; TASE) today announced that its partner Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) (previously Barr Laboratories Inc.) has begun shipping Triamcinolone Acetonide Nasal Spray. Perrigo's partner Teva was the first applicant to file a complete ANDA with a Paragraph IV certification for Nasacort AQ and will be launching the product with 180 days of generic exclusivity. The Hatch Waxman litigation between Teva...

2011-06-13 14:55:39

Robert Storey, Professor of Cardiology at the University of Sheffield's Department of Cardiovascular Science, presented findings today that confirm one in five deaths in the year following a heart attack could be prevented if a new drug, ticagrelor, was used instead of the standard treatment, clopidogrel. Professor Storey's latest findings were presented at the British Cardiovascular Society annual scientific conference in Manchester today (Monday 13 June 2011). Professor Storey has led UK...

2011-06-07 07:00:00

BRIDGEWATER, N.J., June 7, 2011 /PRNewswire/ -- Actors Paul and Mira Sorvino today announce the Diabetes Co-Stars: Cook-Off. This nationwide recipe contest runs from June 7-July 20, 2011 and is a continuation of their work with sanofi-aventis U.S. on the Diabetes Co-Stars awareness campaign, which is designed to help educate people living with diabetes and those who support them. To view the multimedia assets associated with this release, please click:...

2011-06-06 00:00:00

PARIS and TARRYTOWN, N.Y., June 6, 2011 /PRNewswire/ -- Sanofi (EURONEXT: SAN and NYSE: SNY) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that data showing that the investigational agent ZALTRAP(TM) (aflibercept), also known as VEGF Trap, significantly improved survival in previously treated metastatic colorectal cancer patients will be presented at the ESMO World Congress on Gastrointestinal Cancer on June 25, 2011. The abstract (#0-0024) was published in the June...

2011-06-04 07:00:00

PARIS, June 4, 2011 /PRNewswire-FirstCall/ -- - Results of Phase III SAVE-ONCO Study Selected for "Best of ASCO 2011" - - Venous Thrombo-embolism Affects Up to 1 in 5 Cancer Patients And Chemotherapy Further Increases this Risk Sanofi (EURONEXT: SAN and NYSE: SNY) announced today results of the pivotal SAVE-ONCO study which demonstrated that, in cancer patients initiating a chemotherapy regimen, investigational semuloparin significantly reduced the risk of the composite of...

2011-06-04 07:00:00

BRIDGEWATER, N.J., June 4, 2011 /PRNewswire/ -- Sanofi US (EURONEXT: SAN and NYSE: SNY) announced today results of the pivotal SAVE-ONCO study which demonstrated that, in cancer patients initiating a chemotherapy regimen, investigational semuloparin significantly reduced the risk of the composite of symptomatic-deep vein thromboembolism (DVT), non-fatal pulmonary embolism (PE) or venous thromboembolism (VTE)-related death by 64%(i), meeting the study primary endpoint (respectively 1.2%...